GENELUX CORPORATION Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
GENELUX CORPORATION (GNLX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $3.19 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-13
- GENELUX CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $3.60, a 8.86% decline year-over-year.
- GENELUX CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $3.95.
- GENELUX CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $3.06, a 24.90% increase from fiscal 2024.
- GENELUX CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $2.45, a 76.44% decline from fiscal 2023.
- GENELUX CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $10.40, a 0.00% change from fiscal 2022.
- GENELUX CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $10.40.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $3.19 10-Q · filed 2026-08-13 | ||||
| 2026-03-31 | $3.60 10-Q · filed 2026-05-07 | ||||
| 2025-12-31 | $3.06 10-K · filed 2026-03-19 | ||||
| 2025-09-30 | $3.03 10-Q · filed 2025-11-05 | ||||
| 2025-06-30 | $3.64 10-Q · filed 2025-08-07 | ||||
| 2025-03-31 | $3.95 10-Q · filed 2025-05-06 | ||||
| 2024-12-31 | $2.45 10-K · filed 2025-03-28 | ||||
| 2024-09-30 | $2.35 10-Q · filed 2024-11-14 | ||||
| 2024-06-30 | $4.86 10-Q · filed 2024-08-14 | ||||
| 2023-12-31 | $10.40 10-K · filed 2025-03-28 | $22.26 10-K · filed 2024-03-29 | |||
| 2023-09-30 | $22.40 10-Q · filed 2023-11-14 | ||||
| 2022-12-31 | $10.40 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |